Sigrid Therapeutics aims for the consumer market – offers free testing of scientifically proven product against diabetes and obesity ahead of launch

Stockholm, May 16, 2022. Sigrid Therapeutics, an innovative, consumer-focused health company that has developed a new technology, SiPore ® against prediabetes and obesity, announces today that the company, after 10 years of research, is in the starting blocks to launch its new, clinically proven product SiPore21 ® . One hundred and fifty individuals are now being offered a unique opportunity to test the product for free, a tasty gel that is taken with meals, before launch.

Type 2 diabetes is increasing rapidly worldwide and forecasts show that the number of individuals who will be affected by the pre-stage, prediabetes, is expected to exceed half a billion by 2045. At the same time, ill health in the population is increasing due to obesity and abdominal obesity is a known risk factor for developing prediabetes. Sigrid Therapeutics' newly developed treatment for prediabetes and obesity, SiPore21®, has shown promising results in early clinical studies. The product is under development as a medical device in the EU and is classified as a dietary supplement in the US. In 2022, the company will start a large clinical study on a total of 440 patients who are either overweight, obese and suffer from prediabetes or newly diagnosed type 2 diabetes. The study is being conducted at clinics in Germany, Slovakia, Romania and Hungary.

Reduces energy intake

SiPore® technology is based on research at Stockholm University and is based on the properties of silicon, a naturally occurring mineral. SiPore® technology physically prevents some of the digestive enzymes in the intestine from breaking down food, with reduced energy absorption as an effect. SiPore21® is a tasty gel that is taken with meals to control blood sugar and weight. The product has a favorable safety profile as it acts locally in the intestine and does not reach the body's tissues. As the product is made from a naturally occurring mineral, it is gentle on both humans and the environment.

Unique pre-launch program

Sigrid is now starting a unique pre-launch program, where 150 participants are given the opportunity to test the product for free for 6 weeks. Participants take the product twice a day with meals and share their experiences via a questionnaire before and after the program.

Sigrid Therapeutics, co-founder and CEO, Sana Alajmovic comments: “This is a unique opportunity to help us maximize the benefits of a product to combat diabetes and obesity. The number of places in the program is limited and the interest is high. If you are interested in

To participate in the program, you should register your interest on our website www.sigridthx.com .